Reviticell has developed a patented medical device that utilizes modular cartridges to prepare regenerative treatments from a patient's own blood or tissue, enabling precise and consistent outcomes. This technology addresses the complexity and risks associated with preparing these treatments in the operating room, allowing for efficient and effective patient care without the need for traditional laboratory settings.
Funding
$1.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Preparing regenerative treatments from a patient's own blood or tissue in the operating room can be complex and carry inherent risks, leading to inconsistent outcomes. Traditional methods often require specialized laboratory settings, adding to the logistical challenges and costs associated with these procedures.
Solution
Reviticell offers a patented medical device that utilizes modular cartridges to streamline the preparation of regenerative treatments at the point of care. The device is designed to process a patient's own blood or tissue, enabling precise and consistent preparation of regenerative treatments. By automating key steps and minimizing manual handling, the technology reduces the potential for errors and variability, leading to more predictable and reliable therapeutic results. The system is designed for ease of use in clinical settings, eliminating the need for complex laboratory infrastructure and specialized personnel.
Target Audience
The primary target audience includes surgeons, physicians, and medical professionals who perform regenerative medicine procedures in hospitals, clinics, and private practices.
Features
- Modular cartridge system for processing blood or tissue samples
- Automated processing steps to ensure consistency and reduce variability
- Point-of-care application, eliminating the need for external laboratories
- Streamlined workflow for efficient preparation of regenerative treatments